NASDAQ:VRTX - Vertex Pharmaceuticals Price Target & Analyst Ratings

Sign in or create an account to add this stock to your watchlist.
$181.53 -1.03 (-0.56 %)
(As of 03/22/2019 04:00 PM ET)
Previous Close$181.53
Today's Range$181.04 - $183.85
52-Week Range$144.07 - $195.81
Volume1.60 million shs
Average Volume1.33 million shs
Market Capitalization$46.41 billion
P/E Ratio64.14
Dividend YieldN/A

Analyst Ratings

Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
19 Wall Street analysts have issued ratings and price targets for Vertex Pharmaceuticals in the last 12 months. Their average twelve-month price target is $206.5694, suggesting that the stock has a possible upside of 13.79%. The high price target for VRTX is $234.00 and the low price target for VRTX is $165.71. There are currently 7 hold ratings and 12 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.632.712.862.88
Ratings Breakdown: 0 Sell Rating(s)
7 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
19 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
21 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $206.5694$204.6473$202.90$196.3182
Price Target Upside: 13.79% upside9.43% upside24.15% upside9.48% upside

Vertex Pharmaceuticals (NASDAQ:VRTX) Consensus Price Target History

Price Target History for Vertex Pharmaceuticals (NASDAQ:VRTX)

Vertex Pharmaceuticals (NASDAQ:VRTX) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/19/2019Svb LeerinkReiterated RatingOutperform ➝ Market PerformHighView Rating Details
3/19/2019Leerink SwannDowngradeOutperform ➝ Market Perform$185.40MediumView Rating Details
3/7/2019OppenheimerBoost Price TargetOutperform ➝ Outperform$200.00 ➝ $230.00LowView Rating Details
3/6/2019CowenReiterated RatingBuy$220.00MediumView Rating Details
3/6/2019Maxim GroupReiterated RatingHoldMediumView Rating Details
2/6/2019BMO Capital MarketsBoost Price TargetOutperform$234.00HighView Rating Details
1/4/2019CitigroupLower Price TargetBuy ➝ Buy$206.00 ➝ $205.00MediumView Rating Details
1/2/2019Raymond JamesDowngradeOutperform ➝ Market Perform$165.71LowView Rating Details
12/19/2018Morgan StanleyLower Price TargetOverweight ➝ Overweight$211.00 ➝ $210.00HighView Rating Details
12/17/2018GuggenheimInitiated CoverageNeutralMediumView Rating Details
12/17/2018Cantor FitzgeraldReiterated RatingBuy$217.00HighView Rating Details
10/26/2018Piper Jaffray CompaniesLower Price TargetOverweight$217.00MediumView Rating Details
10/26/2018HC WainwrightUpgradeNeutral ➝ Buy$220.00HighView Rating Details
10/24/2018JPMorgan Chase & Co.Reiterated RatingBuyMediumView Rating Details
8/28/2018ArgusBoost Price TargetBuy ➝ Average$200.00HighView Rating Details
8/7/2018Stifel NicolausBoost Price TargetBuy$182.00 ➝ $200.00MediumView Rating Details
7/26/2018Royal Bank of CanadaReiterated RatingBuy$203.00MediumView Rating Details
7/26/2018UBS GroupBoost Price TargetNeutral ➝ Neutral$183.00 ➝ $188.00HighView Rating Details
7/16/2018Jefferies Financial GroupBoost Price TargetBuy$210.00LowView Rating Details
2/13/2018JMP SecuritiesReiterated RatingMarket Outperform ➝ Outperform$200.00 ➝ $211.00LowView Rating Details
2/13/2018Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$195.00 ➝ $196.00LowView Rating Details
2/1/2018Bank of AmericaBoost Price TargetBuy ➝ Buy$180.00 ➝ $197.00HighView Rating Details
2/1/2018BarclaysBoost Price TargetOverweight ➝ Overweight$180.00 ➝ $200.00HighView Rating Details
12/12/2017Deutsche BankInitiated CoverageBuy$175.00HighView Rating Details
10/27/2017Needham & Company LLCReiterated RatingBuy$195.00N/AView Rating Details
10/27/2017Robert W. BairdReiterated RatingBuyN/AView Rating Details
9/29/2017DA DavidsonInitiated CoverageBuy$200.00LowView Rating Details
9/29/2017BTIG ResearchInitiated CoverageBuy ➝ Buy$200.00MediumView Rating Details
7/19/2017Janney Montgomery ScottUpgradeNeutral ➝ Buy$98.00HighView Rating Details
6/2/2017CIBCUpgradeMarket Perform ➝ OutperformLowView Rating Details
(Data available from 3/23/2017 forward)
This page was last updated on 3/23/2019 by Staff

Featured Article: Institutional Investors

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel